US pharma giant Merck & Co (NYSE: MRK) has presented positive results from two pivotal Phase III trials of the ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Sutro Biopharma, Inc.’s STRO share price has surged by 15.10%, which has investors questioning if this is right time to sell.

The small-molecule PIKfyve inhibitor – called VRG50635 – has been administered to the first subject in the phase 1 trial involving healthy volunteers, according to the San Francisco-based ...

Sanofi is tapping San Francisco-based Atomwise for a new AI ... some of the biggest names in pharma and medicine, including Merck & Co, Eli Lilly, and AbbVie. In 2019 they struck a major deal ...

San Francisco's Parkmerced is in the hands of a receiver that will handle operations and maintenance at the sprawling ...

Recursion Pharmaceuticals appointed former FDA principal deputy commissioner Namandjé Bumpus, PhD, and Elaine Sun, the COO and CFO of Mammoth Biosciences, to its board of directors. CAMP4 Therapeutics ...